ADMA

Adma Biologics Inc

10.68

Oct 23 • 3:59 PM ET -0.27 (-2.47%)

10.68

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Peers: GRFS KMDA HRMY VCEL MIRM TAK AUPH PTCT EBS HAE

| Held by: IJR FBT VTI IWM XBI VXF VB IWO IJT SPSM

Scroll to Statements

Index	RUT
Market Cap	2.39B
Enterprise Value	2.46B
Income	168.96M
Sales	512.27M
Book/sh	1.81
Cash/sh	0.61
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	647
IPO	Oct 17, 2013

P/E	15.16
Forward P/E	11.32
PEG	0.51
P/S	4.67
P/B	5.90
P/C	17.59
P/FCF	20.54
EV/EBITDA	10.97
EV/Sales	4.80
Quick Ratio	3.81
Current Ratio	6.97
Debt/Eq	0.50
LT Debt/Eq	0.49
Option/Short	Yes / Yes

EPS (ttm)	0.70
EPS next Y	0.94
EPS next Q	0.20
EPS this Y	21.30%
EPS next Y	18.41%
EPS next 5Y	22.25%
EPS past 3/5Y	- -
Sales past 3/5Y	49.05% 64.60%
EPS Y/Y TTM	-18.53%
Sales Y/Y TTM	8.04%
EPS Q/Q	19.33%
Sales Q/Q	1.98%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	0.98% -0.76%

Insider Own	4.30%
Insider Trans	0.33%
Inst Own	89.68%
Inst Trans	-4.15%
ROA	27.19%
ROE	41.90%
ROIC	27.83%
Gross Margin	64.67%
Oper. Margin	42.26%
Profit Margin	32.98%
SMA20	2.66%
SMA50	8.66%
SMA200	-4.00%
Trades

Shs Outstand	225.36M
Shs Float	214.34M
Short Float	9.61%
Short Ratio	7.73
Short Interest	20.60M
52W High	20.46 -47.80%
52W Low	7.21 48.13%
Volatility	3.27% 3.88%
ATR (14)	0.37
RSI (14)	58.18
Beta	0.66
Rel Volume	0.65
Avg Volume	2.66M
Volume	1,740,991

Perf Week	0.00%
Perf Month	12.18%
Perf Quarter	25.94%
Perf Half Y	-5.15%
Perf YTD	-41.45%
Perf Year	-29.97%
Perf 3Y	246.75%
Perf 5Y	734.38%
Perf 10Y	70.88%
Recom	1.33
Target Price	18.67
Prev Close	10.95
Price	10.68
Change %	-2.47%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-10-26	Resumed	Raymond James	Outperform	$21
Apr-21-26	Initiated	Canaccord Genuity	Buy	$21
Mar-26-26	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jul-19-23	Resumed	Raymond James	Strong Buy	$5
Oct-13-22	Initiated	Mizuho	Buy	$5
Nov-11-21	Upgrade	Raymond James	Outperform → Strong Buy	$5
Nov-09-21	Initiated	Cantor Fitzgerald	Overweight	$4.50
Jun-04-19	Initiated	Jefferies	Buy	$8
Apr-15-19	Reiterated	H.C. Wainwright	Buy	$10 → $13
Feb-07-19	Resumed	H.C. Wainwright	Buy	$10
Dec-11-17	Reiterated	Maxim Group	Buy	$13 → $8
Nov-14-17	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-23-17	Upgrade	Maxim Group	Hold → Buy	$13
Aug-01-16	Downgrade	Maxim Group	Buy → Hold
Jul-25-16	Reiterated	Maxim Group	Buy	$24 → $14
May-13-15	Reiterated	Maxim Group	Buy	$18 → $24
Dec-08-14	Initiated	Oppenheimer	Outperform	$20
Dec-01-14	Reiterated	Maxim Group	Buy	$16 → $18

Show Previous Ratings

Oct-15-26 07:00AM	ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process (GlobeNewswire)
Aug-21-26 04:38AM	ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA (PR Newswire)
Aug-06-26 01:09AM	ADMA Biologics Inc (ADMA) (Q2 2026) Earnings Call Highlights: Ascentiv Surges 24% as Gross ... (GuruFocus.com) +8.64%
Aug-05-26 04:53PM	Adma Biologics: Q2 Earnings Snapshot (Associated Press)
04:05PM	ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
09:38AM	Loading…
Aug-04-26 09:38AM	Earnings To Watch: ADMA Biologics Inc (ADMA) Q2 2026 -- GF Value Sees 149% Upside (GuruFocus.com)
Jul-29-26 07:00AM	ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026 (GlobeNewswire)
Jul-20-26 03:31AM	ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA (PR Newswire)
Jul-06-26 01:57PM	ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA (PR Newswire)
Jun-22-26 04:29AM	ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA (PR Newswire)
May-06-26 05:28PM	Adma Biologics: Q1 Earnings Snapshot (Associated Press) -15.97%
04:05PM	ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-04-26 07:00AM	ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV to Include Pediatric Immune Compromised Patients Two Years of Age and Older (GlobeNewswire)
Apr-29-26 07:00AM	ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026 (GlobeNewswire)
Mar-30-26 03:47PM	ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating (PR Newswire)
07:00AM	Loading…
Mar-27-26 07:00AM	ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research (GlobeNewswire) +11.58%
Mar-25-26 06:30AM	ADMA Biologics Addresses Misleading Short-Seller Report (GlobeNewswire) -15.00%
Mar-10-26 09:55AM	BMY Advances CELMoD Program With Positive Phase III Results (Zacks)
Mar-03-26 12:00PM	Adma Biologics (ADMA) Upgraded to Strong Buy: Here's Why (Zacks)
09:30AM	Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It? (Zacks)
Mar-02-26 07:00AM	ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative (GlobeNewswire) +6.49%
Feb-26-26 11:40AM	Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change (Zacks)
10:54AM	ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance (Zacks)
10:50AM	Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues (Zacks)
12:05AM	ADMA Biologics Inc (ADMA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-25-26 06:32PM	ADMA Biologics Q4 Earnings Call Highlights (MarketBeat)
04:45PM	Adma Biologics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-24-26 07:21AM	What To Expect From ADMA Biologics Inc (ADMA) Q4 2025 Earnings (GuruFocus.com)
Feb-19-26 05:45PM	Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note (Zacks)
10:39AM	Loading…
Feb-18-26 10:39AM	Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026? (Zacks)
07:00AM	ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 (GlobeNewswire)
Feb-17-26 10:01AM	Novocure Gains FDA Approval for Optune Pax to Treat Pancreatic Cancer (Zacks)
Feb-16-26 08:59AM	NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro (Zacks)
Feb-12-26 05:45PM	Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
Feb-02-26 05:50PM	Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider (Zacks)
Jan-29-26 09:30AM	Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views? (Zacks)
Jan-26-26 05:50PM	Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know (Zacks)
Jan-22-26 09:13AM	ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? (Zacks)
Jan-20-26 06:00PM	Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know (Zacks)
Jan-14-26 08:36AM	ADMA Biologics, Inc. (ADMA): A Bull Case Theory (Insider Monkey)
Jan-13-26 05:50PM	Adma Biologics (ADMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
01:28PM	ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook (Zacks)
09:30AM	Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
Jan-12-26 01:47PM	ADMA Biologics Highlights $510M+ 2025 Revenue, Raises 2027 Outlook at JPM Healthcare Conference (MarketBeat)
08:00AM	ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update (GlobeNewswire)
Jan-06-26 05:50PM	Why Adma Biologics (ADMA) Outpaced the Stock Market Today (Zacks)
Jan-05-26 07:00AM	ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026 (GlobeNewswire)
Dec-21-25 08:54AM	ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance (Insider Monkey)
Dec-12-25 09:40AM	Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-05-25 11:30AM	Adma Biologics (ADMA) Up 43.3% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-04-25 09:47AM	Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know (Zacks)
07:57AM	These stocks are new additions to Mizuhos Americas Top Picks list (Investing.com)
Dec-03-25 10:23AM	PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain (Zacks)
10:01AM	AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension (Zacks)
Dec-02-25 10:15AM	MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study (Zacks)
10:09AM	JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis (Zacks)
Dec-01-25 11:41AM	ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know (Zacks)
09:30AM	Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet (Zacks)
Nov-27-25 09:55AM	Wall Street Analysts Think Adma Biologics (ADMA) Could Surge 60.24%: Read This Before Placing a Bet (Zacks)
Nov-25-25 12:00PM	Adma Biologics (ADMA) Upgraded to Buy: Here's What You Should Know (Zacks)
11:10AM	NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies (Zacks)
10:43AM	Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline (Zacks)
09:40AM	Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year? (Zacks)
09:30AM	Adma Biologics (ADMA) Recently Broke Out Above the 200-Day Moving Average (Zacks)
Nov-21-25 10:15AM	AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo (Zacks) +5.01%
Nov-20-25 11:38AM	COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know (Zacks)
09:49AM	MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC (Zacks)
Nov-19-25 10:06AM	VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects (Zacks)
Nov-18-25 11:42AM	VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know (Zacks)
10:33AM	Alector Stock Plummets 63% in a Month: Here's What You Need to Know (Zacks)
Nov-14-25 09:30AM	Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy? (Zacks)
07:36AM	Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
Nov-13-25 09:08AM	Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint (Zacks)
Nov-12-25 09:35AM	Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
09:30AM	Adma Biologics (ADMA) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks)
Nov-11-25 10:37AM	Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks) +8.97%
09:55AM	Wall Street Analysts Believe Adma Biologics (ADMA) Could Rally 108.5%: Here's is How to Trade (Zacks)
Nov-06-25 08:27AM	ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales (Zacks) -8.72%
12:02AM	ADMA Biologics Inc (ADMA) Q3 2025 Earnings Call Highlights: Record Growth and Strategic Advancements (GuruFocus.com)
Nov-05-25 06:25PM	Adma Biologics (ADMA) Q3 Earnings Match Estimates (Zacks) +5.06%
05:20PM	Adma Biologics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-04-25 07:39AM	ADMA Biologics Inc (ADMA) Q3 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Oct-30-25 09:00AM	ADMA Biologics Inc (ADMA) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Oct-29-25 09:30AM	Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It? (Zacks)
07:00AM	ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-27-25 05:50PM	Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider (Zacks)
Oct-16-25 05:50PM	Here's Why Adma Biologics (ADMA) Fell More Than Broader Market (Zacks)
Oct-13-25 09:30AM	Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Oct-10-25 05:50PM	Adma Biologics (ADMA) Stock Moves -1.36%: What You Should Know (Zacks)
Oct-01-25 05:50PM	Why Adma Biologics (ADMA) Outpaced the Stock Market Today (Zacks)
Sep-26-25 09:30AM	Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views? (Zacks)
Sep-25-25 05:50PM	Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors (Zacks)
08:46AM	Are Options Traders Betting on a Big Move in ADMA Biologics Stock? (Zacks)
Sep-22-25 08:23AM	Renaissance Small Cap Growth Strategy Added ADMA Biologics (ADMA) to Its Portfolio in Q2 (Insider Monkey)
Sep-19-25 05:45PM	Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts (Zacks)
Sep-15-25 05:50PM	Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note (Zacks) -5.03%
Sep-10-25 09:30AM	Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic? (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Grossman Jerrold B	Director	May 27 '26	Buy	7.91	6,400	50,624	520,284	May 28 04:05 PM
Grossman Jerrold B	Director	May 12 '26	Buy	8.01	12,500	100,125	513,884	May 14 07:00 AM
Grossman Jerrold B	Director	May 11 '26	Buy	8.01	12,500	100,125	501,384	May 12 05:22 PM
Guiheen Lawrence P.	Director	Mar 13 '26	Option Exercise	3.66	30,000	109,800	135,520	Mar 17 09:00 PM
Grossman Adam S	President and CEO	Mar 16 '26	Option Exercise	5.40	15,000	81,000	2,133,777	Mar 17 09:00 PM
Grossman Adam S	President and CEO	Mar 16 '26	Sale	15.16	21,000	318,360	2,112,777	Mar 17 09:00 PM
Tade Brad L.	Former Officer	Mar 10 '26	Proposed Sale	15.81	50,026	790,911		Mar 10 09:45 PM
Kestenberg-Messina Kaitlin M.	COO and SVP, Compliance	Mar 09 '26	Option Exercise	3.20	10,096	32,331	476,696	Mar 10 09:00 PM
Kestenberg-Messina Kaitlin M.	COO and SVP, Compliance	Mar 09 '26	Sale	15.63	10,096	157,800	466,600	Mar 10 09:00 PM
Kestenberg-Messina Kaitlin M.	Officer	Mar 09 '26	Proposed Sale	15.39	10,096	155,377		Mar 09 09:00 PM
ELMS STEVE	Director	Mar 05 '26	Buy	15.67	7,000	109,690	2,038,730	Mar 09 09:14 AM
ELMS STEVE	Director	Mar 06 '26	Buy	15.39	7,000	107,730	2,045,730	Mar 09 09:14 AM
Grossman Adam S	President and CEO	Feb 17 '26	Option Exercise	5.40	15,000	81,000	2,305,379	Feb 17 09:39 PM
Grossman Adam S	President and CEO	Feb 17 '26	Sale	16.08	21,000	337,680	2,284,379	Feb 17 09:39 PM
Grossman Adam S.	Director	Feb 17 '26	Proposed Sale	16.09	84,000	1,351,560		Feb 17 09:02 PM
Grossman Adam S	President and CEO	Dec 15 '25	Option Exercise	5.40	15,000	81,000	2,028,850	Dec 16 09:00 PM
Grossman Adam S	President and CEO	Dec 15 '25	Sale	19.79	21,000	415,590	2,007,850	Dec 16 09:00 PM
Grossman Adam S	President and CEO	Nov 19 '25	Option Exercise	5.40	15,000	81,000	2,034,850	Nov 21 09:00 PM
Grossman Adam S	President and CEO	Nov 19 '25	Sale	16.00	21,000	336,000	2,013,850	Nov 21 09:00 PM

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Co-FounderMr. Adam S. Grossman

Ph.D.Dr. Jerrold B. Grossman D.P.S.

CFO & TreasurerMr. P. Terence Kohler

COO & Senior VP of ComplianceMs. Kaitlin M. Kestenberg

General CounselMr. Michael Goldstein

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADMA

Adma Biologics Inc

Upgrade your Finviz experience